COMP <GO>
ABT vs VRTX // PIOTROSKI F-SCORE QUALITY
Abbott Laboratories (NYSE) VS. Vertex Pharmaceuticals Incorporated (NASDAQ) • 15-METRIC TALLY: ABT 5
— VRTX 8
■ METRIC PARITY
LAST: $110.16 (+3.73%) • MKT CAP: $183.77B
piotroski-score
8/9
LAST: $553.15 (-1.02%) • MKT CAP: $141.65B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABT VS. VRTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABT | VRTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.40% | 86.20% | -29.80 | VRTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.90% | 20.00% | -8.10 | VRTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.4x | 29.6x | -11.20 | ABT | /valuation <GO> |
| Free Cash Flow Yield | 4.09% | 2.33% | +1.76 | ABT | /fcf-yield <GO> |
| Operating Margin | 18.20% | 34.80% | -16.60 | VRTX | /operating-margins <GO> |
| Net Profit Margin | 14.70% | 32.90% | -18.20 | VRTX | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 8.90% | -3.20 | VRTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.27% | 0.00% | +2.27 | ABT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.36 | 13.86 | -9.50 | VRTX | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.5 | 63.9 | -5.40 | VRTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 1.02 | -0.03 | VRTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.8x | 32.2x | -6.40 | ABT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $183.77B | $141.65B | $42.11B | ABT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABT REV | VRTX REV | ABT GROSS % | VRTX GROSS % | ABT FCF | VRTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $44.33B | $12.00B | 56.4% | 86.2% | $7.39B | $3.19B |
| FY 2024 | $41.95B | $11.02B | 55.4% | 86.1% | $6.35B | -$790.3M |
| FY 2023 | $40.11B | $9.87B | — | — | $5.46B | $3.09B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABT // BETA 0.99
VRTX // BETA 1.02